Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently?
Christian Gege
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 12, pp. 1517-1535
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases
Jiuping Zeng, Mingxing Li, Qianyun Zhao, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 13, Iss. 6, pp. 545-562
Open Access | Times Cited: 27
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies
Giacomo Cozzi, Laura Scagnellato, Mariagrazia Lorenzin, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 8, pp. 503-518
Closed Access | Times Cited: 23
Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets
Lisha Li, Jiaye Lu, Jun Liu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 16
IL-17 in osteoarthritis: A narrative review
Juan Xiao, Ping Zhang, Fang-Lan Cai, et al.
Open Life Sciences (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 21
Macrocyclization strategy for improving candidate profiles in medicinal chemistry
Om Darlami, R.Y.K. Pun, Sung‐Hoon Ahn, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116501-116501
Closed Access | Times Cited: 8
Current therapeutic overview and future perspectives regarding the treatment of psoriasis
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113388-113388
Closed Access | Times Cited: 5
A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians
Anastasia Drakos, Ronald Vender
Dermatology and Therapy (2022) Vol. 12, Iss. 12, pp. 2715-2730
Open Access | Times Cited: 19
Targeting Th17 cells in HIV-1 remission/cure interventions
Augustine Fert, Laurence Raymond Marchand, Tomas Raul Wiche Salinas, et al.
Trends in Immunology (2022) Vol. 43, Iss. 7, pp. 580-594
Closed Access | Times Cited: 17
RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis
Mia Collins, Rikard Pehrson, Hanna Grindebacke, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0317090-e0317090
Open Access
Innovative Approaches to Psoriasis: Small Molecules Targeting Key Signaling Pathways
Meeral Gosia, Gaurav Doshi, Siddhi Bagwe Parab, et al.
Immunological Investigations (2025), pp. 1-37
Closed Access
The cyclin‐dependent kinase inhibitor AT7519 is a human RORγt agonist
Kaja Karaś, Joanna Pastwińska, Anna Sałkowska, et al.
Immunology and Cell Biology (2025)
Closed Access
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities
Nannan Sun, Yonghui Wang
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis
Olaf Kinzel, Steven D. Goldberg, Maxwell D. Cummings, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
RORγt agonist LYC-55716 potentiates IFN-α’s efficacy in hepatocellular carcinoma through enhancing cytotoxicity of Tc17 cells and infiltration of CD8+ T cells
Heng Wang, Guojiang Zhang, Zhao Cai, et al.
Biochemical Pharmacology (2025), pp. 116963-116963
Closed Access
T-helper Transcription Factor Profiling in Peripheral Blood Mononuclear Cells: A Non-invasive Approach to Predicting Disease Stage in Breast Cancer
Maryam Rezaee, Fatemeh Kheiri, Fatemeh Faraji, et al.
Biochemical Genetics (2025)
Closed Access
Investigational systemic drugs for moderate to severe plaque psoriasis: What’s new?
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 3, pp. 229-243
Open Access | Times Cited: 9
Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
Bianca Fiorillo, Rosalinda Roselli, Claudia Finamore, et al.
ACS Omega (2023) Vol. 8, Iss. 6, pp. 5983-5994
Open Access | Times Cited: 8
Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis
Corinna S. Maier, Doerthe Eckert, F. Stephen Laroux, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 5, pp. 474-484
Closed Access | Times Cited: 3
Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity
Alexandra Herrmann, Christian Gege, Christina Wangen, et al.
Antiviral Research (2024), pp. 106008-106008
Open Access | Times Cited: 3
Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
Antibodies (2024) Vol. 13, Iss. 3, pp. 76-76
Open Access | Times Cited: 3
Safety, Tolerability, and Pharmacokinetics of IMU‐935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double‐Blind, Placebo‐Controlled, First‐in‐Human Phase 1 Study
Thomas M. Polasek, Indika Leelasena, Irina Betscheider, et al.
Clinical Pharmacology in Drug Development (2023) Vol. 12, Iss. 5, pp. 525-534
Open Access | Times Cited: 7
Lithocholic acid derivatives as potent modulators of the nuclear receptor RORγt
Somaya A. Abdel‐Rahman, Simone Brogi, Moustafa T. Gabr
RSC Advances (2024) Vol. 14, Iss. 5, pp. 2918-2928
Open Access | Times Cited: 2
Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults
Mohamed‐Eslam F. Mohamed, Yuli Qian, Ronilda D’Cunha, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 7, pp. 801-809
Open Access | Times Cited: 2
Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial
Stephen K. Tyring, Angela Moore, Akimchi Morita, et al.
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 11, pp. 1347-1355
Open Access | Times Cited: 2
Evaluation of the activity of cardiac glycosides on RORγ and RORγT nuclear receptors
Iwona Karwaciak, Joanna Pastwińska, Anna Sałkowska, et al.
Archives of Biochemistry and Biophysics (2024) Vol. 759, pp. 110085-110085
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top